AlphAIAlphAI — Financial news for AI agents
timothysykes.com$GKOS

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

Original reporting
timothysykes.com
Published Oct 29, 2026, 4:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 5:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance — source image
Source · timothysykes.com
Decision brief

The 30-second read

$GKOSBullishHigh
01

Why it matters

The earnings beat and guidance are fresh primary disclosures, driving a large intraday rally.

02

Market read

Earnings surprise and guidance lift GKOS sharply; traders may look for continuation or short‑term pull‑back.

03

What to watch

Negative net margins and potential procedure‑volume headwinds from health‑policy changes.

Relevance 9/10Novelty 9/10Timing: intraday today

Background

Timothy Sykes' outlet highlights the earnings surprise and guidance, adding analyst target lifts.

Company-level read

Ticker impact

$GKOSBullishHigh confidence
Context

Q3 earnings beat with $0.47 EPS vs expected loss and raised 2026 revenue guidance to $775M‑$785M, driving a 33% one‑day stock surge.

Expected impact

upward bias as traders chase momentum and analysts raise targets.

Evidence & confidence

The surprise earnings beat and multi‑year revenue outlook lift sentiment; analyst upgrades reinforce the move.

Market effects

Sector

Positive for ophthalmic device sector as Glaukos' data validates its pipeline.

Regional

U.S. biotech and medical device stocks may see short‑term uplift.

Global

Limited to niche eye‑care market; no broad macro effect.

Counterpoint

What could challenge this read

Rapid price run‑up may attract short sellers; margin pressure and policy headwinds could trigger a pull‑back.

Key entities

  • company
    Glaukos Corporation

    Ophthalmic device maker reporting Q3 results.

  • analyst
    BTIG

    Raised price target to $205.

  • analyst
    Mizuho

    Raised target to $190, noted policy headwinds.

Read at source← All news

StoryGlaukos reports record Q3 sales, beats expectations and lifts 2026‑2027 revenue outlook

Also covered by

5 outlets

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

finance.yahoo.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

timothysykes.com
$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

stockstotrade.com
$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.

investing.com